• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS≥10].

作者信息

Quesada Stanislas, Vaflard Pauline

机构信息

Institut du cancer de Montpellier (ICM), 208, avenue des Apothicaires - Parc Euromédecine, 34298 Montpellier cedex 5, France.

Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.

出版信息

Bull Cancer. 2022 Feb;109(2):111-113. doi: 10.1016/j.bulcan.2021.09.021. Epub 2022 Jan 5.

DOI:10.1016/j.bulcan.2021.09.021
PMID:34998526
Abstract
摘要

相似文献

1
[New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS≥10].新药批准：帕博利珠单抗联合化疗作为晚期/转移性食管癌或HER阴性胃食管腺癌的一线治疗，其PD-L1表达且CPS≥10
Bull Cancer. 2022 Feb;109(2):111-113. doi: 10.1016/j.bulcan.2021.09.021. Epub 2022 Jan 5.
2
[New EMA drug approval: Nivolumab in association with chemotherapy as first line treatment for HER2-negative esophageal adenocarcinoma with PD-L1 expression (CPS≥5)].[欧洲药品管理局（EMA）新批准的药物：纳武利尤单抗联合化疗作为一线治疗用于治疗PD-L1表达（综合阳性评分[CPS]≥5）的HER2阴性食管腺癌]
Bull Cancer. 2022 Feb;109(2):109-110. doi: 10.1016/j.bulcan.2021.11.012. Epub 2022 Jan 4.
3
Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.帕博利珠单抗治疗晚期胃及胃食管结合部腺癌。
Future Oncol. 2018 Feb;14(5):417-430. doi: 10.2217/fon-2017-0436. Epub 2017 Nov 2.
4
[Pembrolizumab+chemotherapy as first-line treatment in patients with HER2 negative advanced oesogastric adenocarcinoma].帕博利珠单抗联合化疗作为HER2阴性晚期食管胃腺癌患者的一线治疗方案
Bull Cancer. 2024 May;111(5):431-432. doi: 10.1016/j.bulcan.2024.01.004. Epub 2024 Mar 7.
5
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.FDA 批准概要：帕博利珠单抗用于表达 PD-L1 的复发性局部晚期或转移性胃或胃食管连接部腺癌。
Oncologist. 2019 Jan;24(1):103-109. doi: 10.1634/theoncologist.2018-0221. Epub 2018 Aug 17.
6
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.帕博利珠单抗联合化疗与单纯化疗一线治疗晚期食管癌（KEYNOTE-590）：一项随机、安慰剂对照、III 期研究。
Lancet. 2021 Aug 28;398(10302):759-771. doi: 10.1016/S0140-6736(21)01234-4.
7
[Pembrolizumab with trastuzumab and chemotherapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinomas with surexpression of HER2 and CPS≥1].帕博利珠单抗联合曲妥珠单抗及化疗用于HER2过表达且CPS≥1的晚期或转移性胃或胃食管交界腺癌
Bull Cancer. 2024 Feb;111(2):130-132. doi: 10.1016/j.bulcan.2023.11.004. Epub 2023 Dec 8.
8
PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma-a commentary on KEYNOTE-811.PD-L1作为帕博利珠单抗在HER2阳性胃或胃食管交界腺癌中的预测生物标志物——关于KEYNOTE-811的评论
Chin Clin Oncol. 2024 Aug;13(4):59. doi: 10.21037/cco-24-28. Epub 2024 Jun 6.
9
Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma.替雷利珠单抗联合化疗用于一线治疗晚期食管鳞状细胞癌和胃/胃食管交界腺癌的安全性和有效性。
Thorac Cancer. 2020 Dec;11(12):3419-3421. doi: 10.1111/1759-7714.13690. Epub 2020 Oct 12.
10
Pembrolizumab versus paclitaxel in gastro-oesophageal adenocarcinoma.帕博利珠单抗与紫杉醇治疗胃食管腺癌的对比
Lancet. 2018 Jul 14;392(10142):97-98. doi: 10.1016/S0140-6736(18)31277-7. Epub 2018 Jun 4.

引用本文的文献

1
High CHAF1A Expression Levels Are Positively-Correlated with PD-L1 Expression and Indicate Poor Prognosis in Gastric Cancer.CHAF1A高表达水平与PD-L1表达呈正相关，并提示胃癌预后不良。
Evid Based Complement Alternat Med. 2022 Jul 19;2022:1323321. doi: 10.1155/2022/1323321. eCollection 2022.